Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients - Alexandre, Marina; Bohelay, Gérôme; Gille, Thomas; Le Roux-Villet, Christelle; Soued, Isaac; Morin, Florence; Caux, Frédéric; Grootenboer-Mignot, Sabine; Prost-Squarcioni, Catherine (Frontiers in immunology, 2022)
Keywords: autoimmune bullous diseases (AIBDs); autoimmune skin diseases; bullous pemphigoid (BP); Immunoglobulin E (IgE); Immunology; mucous membrane pemphigoid (MMP); omalizumab (Xolair); Anti-BP180 IgG; omalizumab (Xolair); autoimmune skin diseases; mucous membrane pemphigoid (MMP); Immunoglobulin E (IgE); bullous pemphigoid (BP); Anti-BP180 IgE; autoimmune bullous diseases (AIBDs)